Dr. Feliciano on ROS1-Targeted Therapy in NSCLC

Josephine L. Feliciano, MD
Published: Wednesday, Aug 15, 2018



Josephine Louella Feliciano, MD, assistant professor of oncology, Johns Hopkins Medicine, discusses ROS1-targeted therapy in patients with non–small cell lung cancer (NSCLC).

ROS1 is a mutation that is similar to an ALK translocation, explains Feliciano. It has a similar configuration in the receptor. Many of the tyrosine kinase inhibitors (TKIs) that are effective for ALK are similarly effective for ROS1. Crizotinib (Xalkori) is approved for ROS1 mutations. Its efficacy reflects high response rates and long durations of response for patients with NSCLC. ROS1 occurs in about 1% of patients with NSCLC and tends to be mutually exclusive of ALK translocations, says Feliciano.

Other ALK inhibitors such as ceritinib (Zykadia) have been studied and show high response rates in ROS1. Lorlatinib is a later-generation TKI that has been shown to be effective in tumors that have become resistant to crizotinib, says Feliciano. However, there are common secondary mutations that can develop on most of these drugs, so physicians are now starting to develop regimens for resistance mutations.


Josephine Louella Feliciano, MD, assistant professor of oncology, Johns Hopkins Medicine, discusses ROS1-targeted therapy in patients with non–small cell lung cancer (NSCLC).

ROS1 is a mutation that is similar to an ALK translocation, explains Feliciano. It has a similar configuration in the receptor. Many of the tyrosine kinase inhibitors (TKIs) that are effective for ALK are similarly effective for ROS1. Crizotinib (Xalkori) is approved for ROS1 mutations. Its efficacy reflects high response rates and long durations of response for patients with NSCLC. ROS1 occurs in about 1% of patients with NSCLC and tends to be mutually exclusive of ALK translocations, says Feliciano.

Other ALK inhibitors such as ceritinib (Zykadia) have been studied and show high response rates in ROS1. Lorlatinib is a later-generation TKI that has been shown to be effective in tumors that have become resistant to crizotinib, says Feliciano. However, there are common secondary mutations that can develop on most of these drugs, so physicians are now starting to develop regimens for resistance mutations.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x